FDA Approves PRRT to Treat Neuroendocrine Tumors
source: pixabay.com

FDA Approves PRRT to Treat Neuroendocrine Tumors

  Patients with inoperable or metastasized neuroendocrine tumors (NETs) may now benefit from recently FDA approved peptide receptor radionuclide therapy (PRRT) according to a recent article in MedPage Today. The…

Continue Reading FDA Approves PRRT to Treat Neuroendocrine Tumors
FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
source: pixabay.com

FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors

  Surufatinib was recently granted Orphan Drug designation by the FDA. This drug was made for the treatment of pancreatic neuroendocrine tumors (PanNETs). It was created by Hutchison China MediTech…

Continue Reading FDA Grants Orphan Drug Designation for Treatment of Pancreatic Neuroendocrine Tumors
Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins
bdyczewski / Pixabay

Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins

According to a story from Central Charts, the drug developer Crinetics Pharmaceuticals, Inc. recently issued an announcement revealing that the company has begun the initialization of a Phase 1 clinical…

Continue Reading Phase 1 Trial of Experimental Treatment for Neuroendocrine Tumors Begins
Study Reveals Combination Therapy for Aggressive, Cancerous Neuroendocrine Tumors
Bru-nO / Pixabay

Study Reveals Combination Therapy for Aggressive, Cancerous Neuroendocrine Tumors

According to a story from EurekAlert!, a recent research study has found that a two part immunotherapy combination treatment has the potential to be a useful treatment for high-grade neuroendocrine…

Continue Reading Study Reveals Combination Therapy for Aggressive, Cancerous Neuroendocrine Tumors

Common Drug Duo Could Treat High-Grade Neuroendocrine Carcinomas

According to a publication from EurekAlert, new research presented at the annual conference of the American Association for Cancer Research (AACR) suggests that a combination therapy of two regularly-administered immunotherapy…

Continue Reading Common Drug Duo Could Treat High-Grade Neuroendocrine Carcinomas

Press Release: ASCO Names Advance of the Year: Progress in Treating Rare Cancers

Progress Report Debuts ASCO’s Research Priorities for the Cancer Community, Emphasizes Impact of Federal Funding FOR IMMEDIATE RELEASE January 31, 2019 Ashley Yum 571-483-1376 ashley.yum@asco.org   ALEXANDRIA, Va. — Over the…

Continue Reading Press Release: ASCO Names Advance of the Year: Progress in Treating Rare Cancers
Close Menu